Opinion|Videos|October 7, 2024
Examining Molecular Differences in PDE4 Inhibitors in Pediatric Patients with Plaque Psoriasis
Author(s)Karan Lal, DO, MS, FAAD, Helen T Shin, MD
Key Takeaways
- Roflumilast is used for COPD, reducing exacerbations but may cause gastrointestinal side effects.
- Apremilast is indicated for psoriatic arthritis and plaque psoriasis, with a favorable safety profile.
Panelists discuss how the two approved PDE4 inhibitors for pediatric plaque psoriasis differ in their systemic treatments, highlighting key differences in efficacy, safety profiles, and patient considerations for optimal use.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Currently there are two approved PDE4 inhibitors in this category. Could you provide an overview of these systemic treatments, highlighting their key differences and considerations in terms of efficacy and safety?
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Oral C5aR Inhibitor INF904 Shows Early Efficacy in HS and CSU Phase 2a Trials
2
Long-Term Strategies and Response Markers in Vitiligo Management
3
Derm Dispatch at SDPA Fall 2025: The Social Media Skin Care Crisis
4
Balancing Social Media's Necessity and AI's Coming Transformation
5
